# A Study to Evaluate JYP0061 Tablets in Patients With Moderate-to-severe Atopic Dermatitis

> **NCT06158490** · PHASE2 · ENROLLING_BY_INVITATION · sponsor: **Guangzhou JOYO Pharma Co., Ltd** · enrollment: 120 (estimated)

## Conditions studied

- Moderate-to-severe Atopic Dermatitis

## Interventions

- **DRUG:** JYP0061 15 mg
- **DRUG:** JYP0061 30 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06158490
- **Lead sponsor:** Guangzhou JOYO Pharma Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2023-12-27
- **Primary completion:** 2026-02-10
- **Final completion:** 2026-10-10
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2025-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06158490

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06158490, "A Study to Evaluate JYP0061 Tablets in Patients With Moderate-to-severe Atopic Dermatitis". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06158490. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*